期刊文献+

肺上叶与下叶社区获得性肺炎患者的临床特点及比较分析 被引量:4

Clinical characteristics and comparative analysis of community acquired pneumonia in patients with upper and lower lobes
原文传递
导出
摘要 目的探讨上叶社区获得性肺炎(CAP)与下叶CAP患者的临床特点。方法采用回顾性分析方法,选择2011年1月至2014年12月期间在上海市肺科医院住院的197例上叶或下叶社区获得性肺炎患者为研究对象,详细收集并整理患者的病史资料,分析上述患者的临床表现、影像学特点、实验室检查,伴发疾病及治疗上的特点,比较上叶CAP与下叶CAP的区别,更进一步了解上叶社区获得性肺炎的临床特点。结果上叶社区获得性肺炎组患者男女比例相仿,下叶CAP组男性为多。上叶社区获得性肺炎组咳嗽患者70/82例,无咳嗽12/82例,以白痰为主;下叶组咳嗽患者相对较多,脓痰患者的比例亦高于上叶肺炎患者。合并胸腔积液较下叶CAP少,上叶社区获得性肺炎组合并胸腔积液的有21/82例,下叶CAP组为63/115例;合并发热比例较下叶相仿,但40℃以上的超高热明显较下叶组少,统计显示上叶肺炎组发热41/82例,40℃以上2/82例;下叶肺炎组发热63/115例,40℃以上11/115例;血白介素6较下叶高,但D-二聚体均值较下叶组低,差异均有统计学意义(P<0.05)。结论上叶CAP临床表现常常不典型,但炎症刺激更为持久,治疗相对更为复杂,抗生素使用应该从重,所需治疗疗程相对较长。 Objective To compare the clinical characteristics between upper lobe community-acquired pneumonia( CAP) and lower lobe CAP. Methods 197 inpatients confirmed CAP in Shanghai Pulmonary Hospital From January 2011 to November 2014 were enrolled. We retrospectively reviewed the medical records of the clinical manifestations,imaging features,laboratory data,complications and treatments. The differences between upper lobe CAP and low lobe CAP were compared. Results The male / female ratio of patients with community-acquired pneumonia in the upper lobes was equal,but men The male / female ratio of patients with community-acquired pneumonia in the upper lobes was equalwere the majority in lower lobe group pneumonia.The patients with white sputum were 70 /82 and 12 /82 patients had no cough in lower lobe group. Lower lobe pneumonia patients with cough and phlegm were more than the upper lobe pneumonia patients. However,the patients with the upper lobe pneumonia complicated with pleural effusion were fewer compared with patients with the lower lobe pneumonia( the upper lobe 21 /82 cases,the lower lobe 63 /115 cases). The number of patients with fever was similar in two groups,while the patients with high temperature( more than 40 ℃) are fewer in upper lobe pneumonia. The upper lobe pneumonia patients with fever were 41 /82 cases,while 2 /82 cases were more than 40 ℃. Likewise,the upper lobe pneumonia patients were 63 /115 cases,and 11 /115 were cases;Moreover,the level of serum interleukin-6 and CD4 were higher in upper lobe pneumonia than that in the lower lobe pneumonia,but the level of serum D-dimmer was lower,the difference was statistically significant( P 0.05). Conclusions The clinical features of CAP in the upper lobes are often atypical,with more enduring inflammation stimulation and relatively more complicated treatment. Consequently,this type of patients should be given relatively large doses of antibiotics and long treatment course.
出处 《中华肺部疾病杂志(电子版)》 CAS 2015年第6期62-65,共4页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 2015年度青年医学人才科研基金课题(WQ2015060)
关键词 社区获得性肺炎 上叶肺炎 下叶肺炎 临床表现 治疗 Community-acquired pneumonia Upper lobe pneumonia Lower lobe pneumonia Clinical manifestations
  • 相关文献

参考文献24

  • 1陈恒屹,崔社怀.重症社区获得性肺炎病死率及预后分析[J].中华肺部疾病杂志(电子版),2010,3(5):16-19. 被引量:15
  • 2刘元明,王茂筠,梁宗安.血清降钙素原鉴别肺结核与社区获得性肺炎的价值[J].西部医学,2014,26(2):166-168. 被引量:12
  • 3徐利萍.血清PCT和CRP检测在社区获得性细菌性肺炎中的应用价值[J].中国微生态学杂志,2014,26(1):69-71. 被引量:19
  • 4吴松,肖秀林,艾红梅.血清PCT、IL-6和CRP检测在社区获得性肺炎中的临床意义[J].国际检验医学杂志,2014,35(14):1940-1941. 被引量:18
  • 5Hna SL, lee HC, Yu CW, et al. Value of procaleitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta- analysis[J]. Int J Tuberc Lung Dis, 2014, 18(4) : 470-477.
  • 6Espafia PP, Capelastegui A, Bilbao A, et al. Utility of two biomarkers for directing care among patients with non-severe community- acquired pneumonia[ J]. Eur J Clin Microbiol Infect Dis, 2012, 31 (12) : 3397-3405.
  • 7Johansson N, Kalin M, Backman-Johansson C, et al. Proealcitonin levels in community-acquired pneumonia-correlationwith aetiology and severity[J]. Scand J Infect Dis, 2014, 46( 11 ) : 787-791.
  • 8Niu WY, Wan YG, Li MY, et al. The diagnostic value of serum pmcalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosi[ J]. Eur Rev Med Pharmacol Sci, 2013, 17(24) : 3329-3333.
  • 9Bello S, Minchol6 E, Fandos S, et al. Inflammatory response in mixed viral-bacterial community-acquired pneumonia [ J ]. BMC Pulm Med, 2014 , 14: 123.
  • 10Tamura M, Watanabe M, Nakajima A, et al. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP) [ J ]. J Infect Chemother, 2014, 20(2): 97-103.

二级参考文献65

  • 1盛瑞媛.中华医学会第十次内科学术会议纪要[J].中华内科杂志,2005,44(2):151-153. 被引量:6
  • 2社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3051
  • 3杨国辉,王广发.临床肺部感染评分对呼吸机相关肺炎患者预后的评价[J].中华结核和呼吸杂志,2006,29(11):751-754. 被引量:46
  • 4陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 5Mofidi R,Suttie SA,Patil PV,et al. The value of procalcitonin at predicting the severity of acute pancreatitis and development o{ in- fected pancreatic necrosis : systematic review [J]. Surgery, 2009, 146(1) :72-81.
  • 6Kim JH, Seo JW, Mok J H, et al. Usefulness of plasma procaleito- nin to predict severity in elderly patients with community-acquired pneumonia[J]. Tuberc Respir Dis(Seoul),2013,74(5):207-214.
  • 7Ahn S,Kim WY,Yoon JY,et al. Procalcitonin in 2009 H1N1 influenza pneumonia:role in differentiating from bacterial pneumonia[J]. Tubere Respir Dis, 2010,68(7) : 205-211.
  • 8Muller B, Harbarth S,Stolz D,et al. Diagnostic and prognostic ac curacy of clinical and laboratory parameters in communityac- quired pneumonia[J]. BMC Infect Dis, 2007,7 (1):10.
  • 9Bafadhel M,Clark TW,Reid C,et al. Procaleitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD[J]. Chest, 2011, 139:1410-1418.
  • 10Feldman C. Pneumonia in the eldly[J].Medical Clinics of North America,2001,(06):1441-1459.

共引文献106

同被引文献44

  • 1Hna SL, lee HC, Yu CW, et al. Value of procaleitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta- analysis[J]. Int J Tuberc Lung Dis, 2014, 18(4) : 470-477.
  • 2Espafia PP, Capelastegui A, Bilbao A, et al. Utility of two biomarkers for directing care among patients with non-severe community- acquired pneumonia[ J]. Eur J Clin Microbiol Infect Dis, 2012, 31 (12) : 3397-3405.
  • 3Johansson N, Kalin M, Backman-Johansson C, et al. Proealcitonin levels in community-acquired pneumonia-correlationwith aetiology and severity[J]. Scand J Infect Dis, 2014, 46( 11 ) : 787-791.
  • 4Niu WY, Wan YG, Li MY, et al. The diagnostic value of serum pmcalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosi[ J]. Eur Rev Med Pharmacol Sci, 2013, 17(24) : 3329-3333.
  • 5Bello S, Minchol6 E, Fandos S, et al. Inflammatory response in mixed viral-bacterial community-acquired pneumonia [ J ]. BMC Pulm Med, 2014 , 14: 123.
  • 6Tamura M, Watanabe M, Nakajima A, et al. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP) [ J ]. J Infect Chemother, 2014, 20(2): 97-103.
  • 7Andrijevic I, Matijasevic J, Andrijevic L, et al. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia[ J]. Ann Thorac Med,2014, 9(3) : 162-167.
  • 8Sahin 17, Yazar E, Yildiz P. Prominent features of platelet count, plateleterit,mean platelet volume and platelet distribution width in pulmonary tuberculosis [ J ]. Muhidiseip Respir Med, 2012, 7 ( 1 ) : 38.
  • 9Moret I, Lorenzo M J, Sarria B, et al. Increased lung neutrophil apoptosis and inflammation resolution in nonresponding pneumonia [J]. Eur Respir J, 2011,38(5) : 1158-1164.
  • 10Dorj G, Hendrie D, Parsons RW, et al. A questionnaire study of injections prescribed and dispensed for patients diagnosed with mild/ moderate community-acquired pneumonia in Mongolia [ J]. Peer J, 2015, 3: e1375.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部